Novartis (NYSE:NVS) shareholders should not begrudge the fact that their management team was willing to put the screws to Alcon's (NYSE:ACL) minority shareholders in the hopes of finishing up the acquisition of this significant eye-care franchise at as low a price as possible. That said, Novartis should also be applauded for seeing reason and finally deciding to offer a fair deal to those Alcon shareholders. Shareholders of companies like Lilly (NYSE:LLY), Bristol Myers (NYSE:BMY) and Sanofi-aventis (NYSE:SNY) might wonder why their management teams are not being similarly aggressive.

IN PICTURES: 5 Tips To Reading The Balance Sheet

The (Successful) End of the Deal
Whether it was a desire to simply finish the deal or the prospect of fighting the Alcon board in court (essentially paying to fight itself, as Novartis already controlled about 77% of the stock), Novartis abandoned its attempt to jerk around the minority shareholders and offer a fair price. To that end, Novartis announced an agreement whereby it will acquire the rest of Alcon for $168 per share. Novartis intends to do the deal with stock, but will supplement it with cash as needed to maintain the deal value. Simultaneously, the company will restart its multi-billion dollar buyback program to neutralize the impact of these extra shares.

All told, Novartis is paying nearly $52 billion for Alcon - nearly 19 times EBITDA and over seven times book value. If that sounds like a high price, it is, but Alcon is arguably worth it. The company has leveraged its leading position in eye care to produce incredible returns on capital and consistent double-digit growth.

A Long Road
While Alcon offered little ground for complaint in its fundamental quality, it also had something of a takeover premium built into the stock for many years. Nestle (Nasdaq:NSRGY) was the majority owner for quite some time, but nobody ever seemed to think that Nestle was really committed to long-term ownership. Consequently, it was not a tremendous surprise to see Novartis step up, but Novartis arguably could have handled the process better. (For more, see Novartis On The Right Track.)

Novartis originally bought a 25% stake in Alcon for $143 per share, and then later exercised an option to acquire the remaining 52% for $180 per share. At that point, Novartis turned around and offered $153 to the remaining Alcon shareholders. Rightly seeing no reason to accept such a discount, shareholders dug in, complained loudly, and prepared to fight it out with Novartis. The fight lasted nearly a year, but ultimately Novartis offered $168 - the average price that it paid to Nestle in those two deals.

Offering the same price to minority shareholders as to Nestle seems like such a blindingly obvious move (at least from the perspective of fairness) that it leads one to wonder what took so long. But perhaps Novartis management felt that they didn't have to offer more than $153 a share and were going to get the deal done as cheaply as possible. (For more, see Novartis Looks For 20/20 Vision With Alcon.)

Where to from Here?
With Alcon in the fold, Novartis has the leading eye-care business in the market and a bit more diversification away from pharmaceuticals (though much of Alcon's business is in pharmaceuticals). That leaves precious few other options for investors, including Allergan (NYSE:AGN) (which is only partially committed to eye care) and ISTA Pharmaceuticals (Nasdaq:ISTA), which is a very interesting stock, but smaller and riskier than big-cap pharma companies.

As for Novartis, it is anyone's guess as to whether this company is done dealing. The company's stock has been among the best performers in the sector over the past year, and carries one of the higher valuations as well. If the company can find accretive or short-term earnings neutral deals where the targets are willing to take Novartis stock, there is no reason to think that the company would not consider certain specialty pharmaceutical, biotech or foreign deals. (For more, see Where The M&A Action Is, And What's Next.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  3. Mutual Funds & ETFs

    ETF Analysis: iShares Morningstar Small-Cap Value

    Find out about the Shares Morningstar Small-Cap Value ETF, and learn detailed information about this exchange-traded fund that focuses on small-cap equities.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has what? Here's what you should consider rather than panicking.
  9. Mutual Funds & ETFs

    ETF Analysis: WisdomTree SmallCap Earnings

    Discover the WisdomTree Small Cap Earnings ETF, a fund with a special focus on small-cap and micro-cap stocks with positive earnings.
  10. Mutual Funds & ETFs

    ETF Analysis: iShares US Regional Banks

    Obtain information and analysis of the iShares US Regional Banks ETF for investors seeking particular exposure to regional bank stocks.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Profit Margin

    A category of ratios measuring profitability calculated as net ...
  3. Quarter - Q1, Q2, Q3, Q4

    A three-month period on a financial calendar that acts as a basis ...
  4. Debt Ratio

    A financial ratio that measures the extent of a company’s or ...
  5. Price-Earnings Ratio - P/E Ratio

    The Price-to-Earnings Ratio or P/E ratio is a ratio for valuing ...
  6. Net Present Value - NPV

    The difference between the present values of cash inflows and ...
  1. What is the formula for calculating compound annual growth rate (CAGR) in Excel?

    The compound annual growth rate, or CAGR for short, measures the return on an investment over a certain period of time. Below ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. When does the fixed charge coverage ratio suggest that a company should stop borrowing ...

    Since the fixed charge coverage ratio indicates the number of times a company is capable of making its fixed charge payments ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. What is the difference between the return on total assets and an interest rate?

    Return on total assets (ROTA) represents one of the profitability metrics. It is calculated by taking a company's earnings ... Read Full Answer >>
  6. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!